- Home
- PROF vs PLRX Comparison
PROF vs PLRX Comparison
Compare PROF & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROF
- PLRX
- Stock Information
- Founded
- PROF N/A
- PLRX 2015
- Country
- PROF Canada
- PLRX United States
- Employees
- PROF N/A
- PLRX N/A
- Industry
- PROF Medical/Dental Instruments
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PROF Health Care
- PLRX Health Care
- Exchange
- PROF Nasdaq
- PLRX Nasdaq
- Market Cap
- PROF 140.9M
- PLRX 90.9M
- IPO Year
- PROF N/A
- PLRX 2020
- Fundamental
- Price
- PROF $4.98
- PLRX $1.46
- Analyst Decision
- PROF Strong Buy
- PLRX Hold
- Analyst Count
- PROF 2
- PLRX 10
- Target Price
- PROF $11.50
- PLRX $9.79
- AVG Volume (30 Days)
- PROF 72.4K
- PLRX 744.6K
- Earning Date
- PROF 05-08-2025
- PLRX 05-20-2025
- Dividend Yield
- PROF N/A
- PLRX N/A
- EPS Growth
- PROF N/A
- PLRX N/A
- EPS
- PROF N/A
- PLRX N/A
- Revenue
- PROF $10,680,000.00
- PLRX N/A
- Revenue This Year
- PROF $71.17
- PLRX N/A
- Revenue Next Year
- PROF $134.25
- PLRX N/A
- P/E Ratio
- PROF N/A
- PLRX N/A
- Revenue Growth
- PROF 48.35
- PLRX N/A
- 52 Week Low
- PROF $3.90
- PLRX $1.10
- 52 Week High
- PROF $11.42
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- PROF 46.29
- PLRX 41.55
- Support Level
- PROF $4.62
- PLRX $1.43
- Resistance Level
- PROF $5.62
- PLRX $1.72
- Average True Range (ATR)
- PROF 0.39
- PLRX 0.11
- MACD
- PROF 0.09
- PLRX 0.05
- Stochastic Oscillator
- PROF 46.51
- PLRX 27.78
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.